Jeffrey Walch
Stock Analyst at Bernstein
(2.60)
# 2,871
Out of 4,534 analysts
11
Total ratings
80%
Success rate
16.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Walch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Reiterated: Sell | $7.7 → $9.8 | $13.50 | -27.41% | 3 | Jun 21, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Hold | $229 | $243.47 | -5.94% | 2 | Jun 8, 2026 | |
| RVMD Revolution Medicines | Maintained: Hold | $151 | $180.39 | -16.29% | 2 | Jun 7, 2026 | |
| BNTX BioNTech SE | Maintained: Hold | $96 | $92.16 | +4.17% | 2 | Jun 4, 2026 | |
| INCY Incyte | Initiated Coverage: Hold | $99 | $115.65 | -14.40% | 1 | May 21, 2026 | |
| NBIX Neurocrine Biosciences | Initiated Coverage: Buy | $221 | $173.00 | +27.75% | 1 | May 21, 2026 |
Summit Therapeutics
Jun 21, 2026
Reiterated: Sell
Price Target: $7.7 → $9.8
Current: $13.50
Upside: -27.41%
Jazz Pharmaceuticals
Jun 8, 2026
Reiterated: Hold
Price Target: $229
Current: $243.47
Upside: -5.94%
Revolution Medicines
Jun 7, 2026
Maintained: Hold
Price Target: $151
Current: $180.39
Upside: -16.29%
BioNTech SE
Jun 4, 2026
Maintained: Hold
Price Target: $96
Current: $92.16
Upside: +4.17%
Incyte
May 21, 2026
Initiated Coverage: Hold
Price Target: $99
Current: $115.65
Upside: -14.40%
Neurocrine Biosciences
May 21, 2026
Initiated Coverage: Buy
Price Target: $221
Current: $173.00
Upside: +27.75%